ACADIA PHARMACEUTICALS INC. - 10-Q Summary (Q1 2025)
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on central nervous system (CNS) disorders and rare diseases. Its commercial portfolio consists of NUPLAZID (pimavanserin) for Parkinson's disease psychosis and DAYBUE (trofinetide) for Rett syndrome. The company operates as a single business segment.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenues | $244,317 | $205,831 |
| Net Income | $18,987 | $16,555 |
| Diluted EPS | $0.11 | $0.10 |
| Operating Cash Flow | $20,323 | $29,079 |
| Cash & Investments (Total) | $681,577 | $755,993 |
| Accumulated Deficit | ($2,185,399) | ($2,414,282) |
Note: Cash & Investments total combines Cash and cash equivalents ($217,696) and Investment securities ($463,881) as of March 31, 2025.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased by 18.7% year-over-year, driven by growth in both NUPLAZID ($159.7M vs. $129.9M) and DAYBUE ($84.6M vs. $75.9M).
- Expense Increases:
- R&D Expenses: Rose to $78.3M from $59.7M, primarily due to increased costs for clinical-stage programs (ACP-101 and ACP-204).
- SG&A Expenses: Increased to $126.4M from $108.0M, driven by consumer activation programs for NUPLAZID and expansion of the DAYBUE commercial team.
- Investing Activities: Net cash used in investing activities surged to $124.0M (from $14.0M) due to significant net purchases of investment securities and a $98.8M outflow for intangible assets.
- Liquidity: Total cash, cash equivalents, and investment securities decreased by approximately $74.4M quarter-over-quarter, attributed to operating cash usage and milestone payments to Neuren Pharmaceuticals.
Guidance, Outlook, and Risks
- Pipeline Progress: The company is advancing ACP-101 (Prader-Willi syndrome) in Phase 3 and ACP-204 (Alzheimer's disease psychosis) in Phase 2. A Phase 2 study for ACP-204 in Lewy Body Dementia is planned for Q3 2025.
- Strategic Discontinuation: In May 2025 (subsequent event), the company decided to discontinue two research programs under its collaboration with Stoke Therapeutics (MECP2 and an undisclosed neurodevelopmental target).
- Legal Proceedings:
- Patent Litigation: Awaiting final court decision in Pimavanserin II cases against MSN and Aurobindo; oral argument scheduled for June 2025 in the Pimavanserin I appeal against MSN.
- Securities Litigation: Expert discovery in the securities class action is scheduled to close in June 2025. A related derivative suit is stayed pending the outcome of the class action.
- Outlook: Management expects cash and investments to fund operations through and beyond the next 12 months. Future capital requirements depend on clinical trial progress, regulatory approvals, and potential business development activities.
Investor Verification Checklist
- Verify the status and timeline of the Phase 3 COMPASS PWS study for ACP-101 and the Phase 2 study for ACP-204 in Alzheimer's disease psychosis.
- Monitor the outcome of the patent infringement litigation against MSN and Aurobindo, specifically the pending court decision in the Pimavanserin II cases.
- Assess the impact of the discontinuation of Stoke Therapeutics programs on the pipeline and potential cost savings.
- Review the milestone payment obligations to Neuren Pharmaceuticals, particularly regarding the $455M potential milestones for DAYBUE.
- Track the regulatory status of DAYBUE in the EU, where a marketing authorization application was submitted in January 2025.